Medpace Holdings, Inc. $MEDP Shares Sold by GW&K Investment Management LLC

GW&K Investment Management LLC decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 23.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 198,261 shares of the company’s stock after selling 61,442 shares during the period. Medpace comprises approximately 0.9% of GW&K Investment Management LLC’s portfolio, making the stock its 16th biggest holding. GW&K Investment Management LLC’s holdings in Medpace were worth $101,941,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of MEDP. Quent Capital LLC acquired a new stake in Medpace during the 3rd quarter worth about $25,000. Optiver Holding B.V. acquired a new position in Medpace in the 3rd quarter valued at approximately $27,000. Root Financial Partners LLC purchased a new stake in shares of Medpace during the third quarter worth $38,000. Geneos Wealth Management Inc. raised its stake in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its position in Medpace by 35.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after acquiring an additional 27 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Leerink Partners cut their target price on Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday, February 11th. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price for the company in a research report on Friday, February 13th. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Zacks Research cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Finally, Royal Bank Of Canada assumed coverage on shares of Medpace in a report on Tuesday. They set an “outperform” rating and a $522.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $486.67.

Medpace Stock Up 0.1%

MEDP opened at $465.86 on Thursday. The stock’s 50 day moving average price is $537.93 and its two-hundred day moving average price is $538.85. The firm has a market capitalization of $13.22 billion, a P/E ratio of 30.45, a price-to-earnings-growth ratio of 2.23 and a beta of 1.44. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.Medpace’s revenue for the quarter was up 32.0% compared to the same quarter last year. During the same period in the prior year, the business earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.